human clinical trials
Scope
Date
~
-
Bio & Pharma
LegoChem Bio receives FDA approval for phase 1,2 trials of LCB84
South Korean pharmaceutical firm LegoChem Biosciences Inc. announced on Thursday that it has received approval from the US Food and Drug Administrat...
Jun 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA
Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean ph...
Jun 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Cellid applies for Phase 3 clinical trials in S.Korea for COVID-19 vaccine
South Korean bio-venture Cellid Co. announced on Tuesday that it has applied for the clinical Phase 3 trial of the COVID-19 Omicron variant-specific...
May 23, 2023 (Gmt+09:00)
-
Artificial intelligence
Virtual human YT debuts as SSG.COM’s shopping host
SSG.COM, the e-commerce brand of South Korean retail giant Shinsegae Inc., announced on Tuesday that virtual human YT has been named the official sh...
May 09, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Bertis releases two academic findings at AOHUPO conference
Bertis, South Korean company specializing in the development of proteomics-based precision medicine technology, announced on Monday that it presente...
May 08, 2023 (Gmt+09:00)
-
Corporate governance
Hyosung’s sibling feud continues with second son in court on trial
It all began in July 2014 when Cho Hyun-joon, currently the Hyosung Group chairman, was sued by his younger brother Cho Hyun-moon on charges of embe...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Artificial intelligence
SK Telecom, Golfzon develop AI golf platform
An artificial intelligence platform in South Korea has produced a golfing coach that analyzes and diagnoses problems in swing posture and recommends...
Apr 27, 2023 (Gmt+09:00)
-
Entertainment
HYBE bets big on AI; to unveil generative AI project in May: Chairman Bang
HYBE Co. is set to wow the world again but this time with the much-hyped generative artificial intelligence technology as it plans to unveil an unpr...
Apr 27, 2023 (Gmt+09:00)
-
Bio & Pharma
CG Bio establishes US corporation to develop tissue products
South Korean bio-regenerative medical firm CG Bio has launched a new US corporation CG MedTech, to focus on the development and marketing of tissue ...
Apr 25, 2023 (Gmt+09:00)
-
Electronics
Samsung faces $303 mn jury verdict in memory patent lawsuit in US
Samsung Electronics Co. lost a semiconductor patent infringement lawsuit filed in the US. The South Korean company received a jury verdict to pay ab...
Apr 23, 2023 (Gmt+09:00)
-
Bio & Pharma
AbClon shows promising results in clinical tests of leukemia treatment
South Korean companies are standing out in the global competition to develop chimeric antigen receptor T-cell (CAR-T) treatments, dubbed "dream" a...
Apr 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer
South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...
Apr 14, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Bio & Pharma
JW Pharma to use zebrafish in new drug development
South Korean drug developer JW Pharmaceutical has entered into a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institu...
Apr 10, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB Cell develops organoid biomaterial based on human normal cells
HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeede...
Apr 06, 2023 (Gmt+09:00)
-
Artificial intelligence
S.Korea's Elice, FuriosaAI to develop training for AI semiconductor talent
South Korea's artificial intelligence (AI) digital education provider Elice on Tuesday said it signed a memorandum of understanding with the AI semi...
Mar 28, 2023 (Gmt+09:00)
-
Artificial intelligence
S.Korean startup DeepBrain AI unveils 3D virtual human B2B technology
South Korean AI startup DeepBrain AI has unveiled a 3D virtual human B2B technology that can engage in real-time conversations, display emotional ex...
Mar 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Boryung, Axiom Space to set up JV to explore space healthcare options
South Korea's Boryung Corp., just decades ago a mom-and-pop pharmacy, will bring its healthcare expertise to space with Axiom Space Inc., a US comme...
Mar 21, 2023 (Gmt+09:00)
-
Cloud computing
Korea's LG CNS launches cloud cost optimization service
LG CNS, a South Korean company specializing in digital transformation, announced on Tuesday the launch of its new service called "FinOps" Clinic.Fin...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's FutureChem gets approval for phase 3 clinical trials in China
South Korean radiopharmaceutical development company FutureChem Co. announced on Thursday that China's National Medical Products Administration (NMP...
Mar 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation
Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...
Mar 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korean biotech NKMax’s unit aims for US IPO
NKMax Co., a South Korean cancer drug maker, is in talks with local and foreign investors in a bid to list its California-based unit NKGen Biotech I...
Mar 14, 2023 (Gmt+09:00)
-
Beauty & Cosmetics
CGBio opens cosmetic surgery clinic in Bali using bio-medical tech
CGBio, a South Korean bio-renewable medical company, announced on Monday that it opened a medical esthetic clinic, called Nulook, in Bali, Indonesia...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
OliX's hair loss treatment candidate approved for clinical trial in Australia
South Korea's OliX Pharmaceuticals has received approval from Australia's Human Research Ethics Committees (HREC) to plan a phase 1 clinical trial o...
Mar 10, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma to develop mRNA flu vaccine with Canadian pharma
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...
Mar 09, 2023 (Gmt+09:00)
-
Venture capital
SK Networks invests $22 mn in US AI-based device company
South Korea's SK Networks has identified a startup specializing in AI-based devices and software platforms as a new investment target. The startup, ...
Mar 09, 2023 (Gmt+09:00)
-
Upcoming IPOs
Korea’s sole foreign clinic operator CHA Healthcare to go public in 2025
CHA Healthcare Co. operating nearly 90 hospitals and infertility treatment centers across the world, is set to pave the way for South Koreans' inves...
Mar 08, 2023 (Gmt+09:00)
Latest News
- 1 BMW surpasses Mercedes in Korean sales amid imported car market shake-up
- 2 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 3 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 4 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 5 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google